{"id":62221,"date":"2025-11-18T07:05:41","date_gmt":"2025-11-18T06:05:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/"},"modified":"2025-11-18T07:05:41","modified_gmt":"2025-11-18T06:05:41","slug":"avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/","title":{"rendered":"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nMVM Partners joins as Avanzanite\u2019s first institutional investor.<\/li>\n<li>\nFunding will scale Avanzanite\u2019s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions.<\/li>\n<li>\nIn just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines.<\/li>\n<li>\nAvanzanite\u2019s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter.<\/li>\n<li>\nAvanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe.<\/li>\n<li>\nA new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind.<\/li>\n<\/ul>\n<p>AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/biopharma?src=hash\" target=\"_blank\">#biopharma<\/a>&#8211;Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a \u20ac32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/5\/Adam_1_hires-2020_pp.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/22\/Adam_1_hires-2020_pp.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/5\/Adam_1_hires-2020_pp.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/21\/Adam_1_hires-2020_pp.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2644606\/5\/PRESS_LOGO_Avanzanite_-_Stacked_logo_-_Dark_Green.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2644606\/22\/PRESS_LOGO_Avanzanite_-_Stacked_logo_-_Dark_Green.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2644606\/5\/PRESS_LOGO_Avanzanite_-_Stacked_logo_-_Dark_Green.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2644606\/21\/PRESS_LOGO_Avanzanite_-_Stacked_logo_-_Dark_Green.jpg\"><\/a><\/p>\n<p>\nThe announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite\u2019s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio.<\/p>\n<p>\nAvanzanite was built to solve Europe\u2019s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings together commercial excellence, scientific expertise, and deep functional capability across market access, pricing and reimbursement. This fully integrated approach enables biotech and pharma innovators to bring rare disease medicines to patients across all 32 European markets \u2013 an area where traditional go-to-market models often fail.<\/p>\n<p>\n\u201cWe are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital \u2013 it demonstrates conviction in our mission and belief in the \u2018Champions League\u2019 team that powers Avanzanite,\u201d said Adam Plich, Founder and CEO of Avanzanite. \u201cWith MVM\u2019s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances \u2013 setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we\u2019ve come, it is just the beginning of our journey,\u201d concluded Plich.<\/p>\n<p>\nIn just three years, with three strategic alliances, Avanzanite has become the partner of choice for biotech and pharma innovators seeking to unlock the full European potential of their orphan medicines. Avanzanite\u2019s current portfolio comprises three medicines across nephrology, ophthalmology and haematology with exclusive licensing or distribution rights in countries across the European Economic Area, the UK and Switzerland.<\/p>\n<p>\nMVM is investing up to \u20ac32 million from its \u20ac500 million sixth fund. In addition, MVM has reserved significant capital to drive Avanzanite\u2019s growth beyond the current round. MVM is Avanzanite\u2019s first institutional investor and joins the company\u2019s Board of Directors.<\/p>\n<p>\nDr. Jack Tanaka, Partner at MVM commented, \u201cFor years MVM has watched promising rare disease medicines struggle to find a path to patients &#8211; Avanzanite breaks this pattern. In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe.\u201d<\/p>\n<p>\n<b>About Avanzanite Bioscience<\/b><\/p>\n<p>\nAvanzanite redefines launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the Netherlands, we partner with biotech and pharma innovators to unlock the full value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe\u2019s complex landscape like master chess players \u2013 ensuring <b>no patient is left behind <\/b>while rewarding biotech and pharma innovators for their commitment to developing breakthrough therapies. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avanzanite.com&amp;esheet=54358427&amp;newsitemid=20251117345890&amp;lan=en-US&amp;anchor=www.avanzanite.com&amp;index=1&amp;md5=432decb29fb7d57f2157c2e7cd2d6573\" rel=\"nofollow\" shape=\"rect\">www.avanzanite.com<\/a><\/p>\n<p>\n<b>About MVM Partners<\/b><\/p>\n<p>\nMVM has invested in high-growth healthcare businesses since 1997. With teams in Boston, London and the San Francisco Bay Area, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mvm.com&amp;esheet=54358427&amp;newsitemid=20251117345890&amp;lan=en-US&amp;anchor=www.mvm.com&amp;index=2&amp;md5=665b257e071e077483f3b8df187d10dc\" rel=\"nofollow\" shape=\"rect\">www.mvm.com<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nAvanzanite Bioscience B.V.<br \/>\n<br \/>Phone: +31 20 301 21 13<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"mailto:media&#64;&#97;&#118;&#97;&#110;&#122;&#97;&#110;&#105;&#116;&#101;&#46;&#99;&#111;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x6d;&#x65;&#x64;&#x69;&#97;&#64;&#97;va&#x6e;&#x7a;&#x61;&#x6e;&#x69;&#116;&#101;&#46;co&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MVM Partners joins as Avanzanite\u2019s first institutional investor. Funding will scale Avanzanite\u2019s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite\u2019s Q3 2025 revenue tripled year-on-year and climbed &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62221","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MVM Partners joins as Avanzanite\u2019s first institutional investor. Funding will scale Avanzanite\u2019s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite\u2019s Q3 2025 revenue tripled year-on-year and climbed ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T06:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/22\/Adam_1_hires-2020_pp.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners\",\"datePublished\":\"2025-11-18T06:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/\"},\"wordCount\":683,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117345890\\\/en\\\/2645633\\\/22\\\/Adam_1_hires-2020_pp.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/\",\"name\":\"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117345890\\\/en\\\/2645633\\\/22\\\/Adam_1_hires-2020_pp.jpg\",\"datePublished\":\"2025-11-18T06:05:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117345890\\\/en\\\/2645633\\\/22\\\/Adam_1_hires-2020_pp.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117345890\\\/en\\\/2645633\\\/22\\\/Adam_1_hires-2020_pp.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/","og_locale":"en_US","og_type":"article","og_title":"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners - Pharma Trend","og_description":"MVM Partners joins as Avanzanite\u2019s first institutional investor. Funding will scale Avanzanite\u2019s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite\u2019s Q3 2025 revenue tripled year-on-year and climbed ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-18T06:05:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/22\/Adam_1_hires-2020_pp.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners","datePublished":"2025-11-18T06:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/"},"wordCount":683,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/22\/Adam_1_hires-2020_pp.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/","url":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/","name":"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/22\/Adam_1_hires-2020_pp.jpg","datePublished":"2025-11-18T06:05:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/22\/Adam_1_hires-2020_pp.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251117345890\/en\/2645633\/22\/Adam_1_hires-2020_pp.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avanzanite-bioscience-secures-e32m-series-a-investment-from-mvm-partners\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avanzanite Bioscience Secures \u20ac32M Series A Investment from MVM Partners"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62221"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62221\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}